Skip to main content

Drug Interactions between fludeoxyglucose f18 and Rolaids Advanced

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

magnesium hydroxide fludeoxyglucose F-18

Applies to: Rolaids Advanced (calcium carbonate / magnesium hydroxide / simethicone) and fludeoxyglucose f18

MONITOR: Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.

MANAGEMENT: Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake. Separation of the diagnostic test and the interfering agent may be advisable in some instances. Package labeling and local protocols should be consulted for further information.

References (3)
  1. "Multum Information Services, Inc. Expert Review Panel"
  2. Cerner Multum, Inc. "Australian Product Information."
  3. mayer d, Bednarczyk EM (2002) "Interaction of colony-stimuating factors and fluorodeoxyglucose f(18) positron emission tomography." Ann Pharmacother, 36, p. 1796-9

Drug and food interactions

Moderate

calcium carbonate food

Applies to: Rolaids Advanced (calcium carbonate / magnesium hydroxide / simethicone)

ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.

MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.

References (6)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
  3. Cerner Multum, Inc. "Australian Product Information."
  4. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  5. Mangels AR (2014) "Bone nutrients for vegetarians." Am J Clin Nutr, 100, epub
  6. Davies NT (1979) "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc, 38, p. 121-8

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer